It has been suggested that the activation of the complement pathway within ischemic myocardium can promote the increased recruitment of intracardiac inflammatory cells, which then results in further myocardial injury.1-3 There has been increasing evidence from both animal and clinical studies that complement split products are formed in ischemic myocardium. With the activation of the complement cascade, the split products C3a and C5a are generated, resulting in increased activation of polymorphonuclear leukocytes (PMNs) , which then adhere to the vascular endothelium and further occlude the coronary microcirculation, potentially resulting in a no-reflow phenomenon. [4] [5] [6] Further experiments have demonstrated that the anaphylatoxins C3a and C5a constrict vascular smooth muscle and thereby cause a significant decrease in coronary flow by increasing the arterial vascular resistance. 7, 8 Longhurst et a19 have shown that intracoronary administration of purified porcine C5a in swine produces reductions in both coronary blood flow and left ventricular function. In addition, several studies have shown that the complement system is an important mediator in acute myocardial ischemia. However, it is not clear whether the complement activation that occurs causes myocardial injury with impaired cardiac contractile function.10-13 Therefore, it has been suggested that activation of the complement system of proteins may be an important mechanism in the pathogenesis of postischemic injury, but questions remain regarding the significance of this complement activation.
The activation of the complement system in response to ischemia could result in either direct complementmediated injury or injury secondary to complementmediated neutrophil infiltration and activation with the generation of toxic oxygen free radicals. [14] [15] [16] [17] We developed an isolated rat heart model in which the effects of isolated cellular or humoral factors on contractile function, coronary flow, cellular adhesion, and free radical generation can be readily studied. In this isolated rat heart model, we performed studies using a recombinant form of complement receptor 1, sCR1, which was genetically engineered to lack both the transmembrane as well as the cytoplasmic domains, resulting in a soluble molecule. This sCR1 has been previously shown to be highly effective at suppressing both the classical and the alternative complement pathways. 18 In the present study, we performed the first experiments to determine the efficacy of sCR1 in preventing postischemic contractile dysfunction. Further experiments were performed to determine the effect of sCR1 on PMN adhesion, complement deposition, and free radical generation. These experiments demonstrate that complement activation is required for PMN-mediated reperfusion injury and that sCR1 is highly effective at preventing this injury. It was observed that the process of PMN adhesion was independent of complement, whereas complement was required for activation of the PMN mediated oxidative burst. sCR1 was shown to effectively block complement-mediated PMN free radical generation.
Methods

Isolated Heart Perfusion
Female Sprague-Dawley rats (weight, 250 to 400 g) were heparinized and anesthetized with intraperitoneal pentobarbital. The hearts were excised, the ascending aorta was cannulated, and retrograde perfusion was initiated. The hearts were then perfused with Krebs bicarbonate perfusate (17 mmol/L glucose, 120 mmol/L sodium chloride, 25 mmol/L sodium bicarbonate, 2.5 mmol/L calcium chloride, 0.5 mmol/L EDTA, 5.9 mmol/L potassium chloride, and 1.2 mmol/L magnesium chloride) at 37°C with a constant pressure of 80 mm Hg. The perfusate was bubbled with 2 /min of 95% 02-5% CO2 gas. A sidearm in the perfusion line allowed infusion of leukocytes and plasma directly into the heart (Fig 1, top) . To measure contractile function, a latex balloon was inserted through an opening in the left atrium across the mitral valve into the left ventricular cavity and connected to a pressure transducer as described previously.14 The balloon was initially inflated with a volume of distilled water sufficient to produce an end-diastolic pressure in the range of 8 to 14 mm Hg. Subsequent measurements of developed pressures were calculated as the difference between the peak systolic and end-diastolic pressure. Left ventricular pressure was recorded with a Gould RS3400 fourchannel recorder. Coronary flow and heart rates were measured periodically every 5 minutes before ischemia and after 20 minutes of global ischemia for 45 minutes of reperfusion.
Leukocyte (PMN) Preparation
Human neutrophils were prepared by the method of Kensler and Trush,19 which yields PMNs with a purity of >95%. Freshly sampled blood (50 mL) was drawn from volunteer donors in heparinized 10-mL vacutainers and centrifuged at 500g in a Beckman TJ-6 for 10 minutes. The plasma and buffy coat were aspirated, leaving the red cell layer. The cells were then mixed with an equal volume of 6% dextran (1 g 500 K, 5 g 80 K, and 100 mL 0.9% normal saline), with the tubes rinsed thoroughly to secure all the cells. The mixture was then transferred to 30-mL plastic syringes that were inverted and incubated at 37°C for 1 hour until a clear separation was obtained. Next, the upper layer was ejected through a 16-gauge needle with a 90' bend into 50-mL plastic centrifuge tubes and spun for 10 minutes at 500g. The 
Preparation of Human Plasma
Human plasma was obtained from healthy donors after whole blood was centrifuged for the isolation of neutrophils. The human plasma was treated with homogenized rat heart tissue to absorb any cross-reactive antibodies to rat heart antigens. The rat heart tissue was homogenized in a tissue grinder (Omni 5000) in the presence of 25 mL Dulbecco's phosphate-buffered saline. Subsequently, this tissue was centrifuged in a high-speed centrifuge at 5000g for 30 minutes at 40C. This step was repeated three times until the supernatant was clear. The pellet was then incubated in the presence of 10 mL of human plasma at 40C for 20 minutes. After this incubation, the immunoabsorbed plasma was separated from the heart tissue by centrifugation at 40C. The plasma was then aspirated into a 50-mL centrifuge tube and stored on ice for use, and the homogenized rat heart tissue pellet was discarded.
WSEONPERIOD Electron Paramagnetic Resonance Measurements
Hearts were isolated and perfused as described above except that no EDTA was included in the perfusate in each of the groups. The experimental protocol remained the same except that the spin trap 5,5 -dimethyl-1-pyroline-N-oxide (DMPO) was infused through a second sidearm located at the level of the heart with a final concentration of 40 mmol/L, as described previously.'4 Periodic collections of the effluent were made in 20-second aliquots during the control period and also for the first 2, 5, 7.5, and 10 minutes during reperfusion. In addition, experiments were performed to detect the generation of oxygen free radicals from PMNs plus plasma in the presence or absence of zymosan, an activator of the complement cascade. 20 frequency of 100 kHz, modulation amplitude of 0.5 G, microwave power of 20 mW, microwave frequency of 9.77 GHz, and acquisitions of 10 1-minute scans. The digitized Bruker spectral data files were transferred to an AST 386 personal computer for analysis. Software capable of isotropic spectral simulation, developed in this laboratory, was used for component analysis of experimental spectra as described previously.21 Spectral simulations consisting of linear combinations of the component signals were performed to match the observed spectra. From the weighted intensities of each component in these simulations, the relative amount of each component signal was determined. The total radical concentration was then determined from the ratio of the double integral of the observed spectra to the known concentration of 2,2,6,6-tetramethylpiperidinoxy (TEMPO) free radical in aqueous solution.
Immunohistochemistry
Immunocytochemical staining was performed on hearts removed from female Sprague-Dawley rats weighing 250 to 400 g that had been perfused in the presence or absence of sCR1. Hearts were quickly removed from the cannula and embedded in OCT compound (Miles Scientific, Naperville), immediately quick-frozen in liquid nitrogen, and stored at -700C 
Measurement of Complement Activation
Measurement of complement activation by red cell lysis assay was performed to determine if the mixture of human PMNs and rat plasma caused any nonspecific activation of complement. In these assays, 0.4 mL of the PMN-containing buffer and 0.1 mL plasma were added to 0.5 mL packed human blood cells and incubated at 37°C for 30 minutes. The red blood cells were then pelleted by centrifugation at 50g for 5 minutes. Spectrophotometric measurements of hemoglobin in the supernatant solution were then performed. No hemolysis was observed on mixing the PMNs and plasma, which demonstrated that there was no nonspecific complement activation. On addition of the complement activator zymosan (1 mg/mL), however, marked hemolysis was observed.
Chemicals
Zymosan and other chemicals used were purchased from Sigma Chemical Co. Double-distilled deionized water was used to prepare the perfusate and other solutions. DMPO, 97% pure, was purchased from Aldrich Chemical Co and further purified by double distillation. Recombinant sCR1 was provided by T Cell Sciences, Boston, Mass.
Experimental Protocol
After a 10-to 15-minute equilibration period, baseline left ventricular developed pressure, left ventricular end-diastolic pressure, and coronary flow were measured (Fig 1, bottom) . The hearts were subjected to a 1-minute preischemic control infusion with PMNs and plasma and then were allowed to equilibrate again with Krebs bicarbonate buffer for a period of 10 minutes, during which measurements of coronary flow and developed pressure were noted. Hearts subsequently received a 30-second infusion of PMNs and plasma with or without sCR1 before the onset of the 20-minute period of 37°C global ischemia. At the onset of ischemia, the balloon was deflated. The intraventricular balloon volume was then reinflated with the same volume as previously used to set the baseline end-diastolic pressure immediately after the onset of reflow. At the onset of reperfusion, the hearts were reperfused for the first 5 minutes with PMNs and plasma in the presence or absence of sCR1, after which perfusion was continued with Krebs buffer alone for a total of 45 minutes of reflow, during which time serial measurements of coronary flow and developed pressure were performed every 5 minutes. One or more sidearm ports were placed just above the aortic cannula, allowing administration of cells, plasma, or both (Fig 1, top) . To determine free radical generation, hearts were similarly perfused in each of the groups in the presence of 40 mmol/L DMPO, as described above.
Two sets of experiments were performed-one in which rat plasma was used and the other in which immunoabsorbed human plasma was used-to access the efficacy of sCR1 at inhibiting both human complement and rat complement. Therefore, there were four experimental groups, with 10 hearts in each group. Group 1. Hearts were subjected to ischemia and reperfusion in the presence of PMNs and rat plasma, without sCR1. The PMNs were suspended in 5 mL of Dulbecco's phosphate-buffered saline with 0.1% glucose and then infused during a 1-minute preischemic control infusion, a 30-second period prior to ischemia, and then again during the first 5 minutes of reperfusion. The cells and plasma were infused through a sidearm at 1:20 dilution to achieve a final concentration of 300 000 PMNs/mL. Group 2. Hearts were subjected to ischemia and reperfusion in the presence of PMNs and rat plasma, in the presence of sCR1 suspended in plasma. The PMNs and plasma were infused as described for group 1. The final concentration of sCR1 administered to hearts was 10 pug/mL. Group 3. Hearts were subjected to ischemia and reperfusion in the presence of PMNs and immunoabsorbed human plasma, in the absence of sCR1. The PMNs and plasma were infused as described in group 1.
Group 4. Hearts were subjected to ischemia and reperfusion in the presence of PMNs and immunoabsorbed human plasma, in the presence of sCR1. PMNs and plasma were infused as described for group 1. The final concentration of sCR1 administered to hearts was 10 gg/mL.
Validation of the Model
The present model was developed to enable the study of the effect of isolated cellular and humoral factors on myocardial contractile function and cellular injury in the postischemic heart, as described previously.14 In the present study, we sought to determine the efficacy of sCR1 at inhibiting either rat or human complement thereby preventing neutrophil-mediated myocardial reperfusion injury.
Human PMNs can be isolated in large numbers, 30 to 60 million, and can be readily purified from other blood elements by procedures that do not result in activation of the cells. In practice, 50 mL blood is required to isolate sufficient cells for one or two experiments. Therefore, human PMNs are used in this model. To similarly isolate this number of PMNs from the rat, complete phlebotomy of 10 animals would be required, and it is difficult to purify the cells to >70% purity.
On infusion of rat plasma in rat hearts, no toxicity was seen and no alterations in left ventricular developed pressure occurred. To verify that the human PMNs did not activate rat complement or cause other adverse reactions, all hearts studied were first subjected to control preischemic infusion of both the PMNs and plasma, and it was observed in all hearts studied that after infusion the left ventricular developed pressure and coronary flow were not significantly altered. In contrast, if complement was activated with 1 mg/mL phorbol 12-myristate 13-acetate, marked sustained injury was observed with a >60% decrease in contractile function. To further validate the observations that mixture of the human PMNs and rat plasma did not cause PMN activation, EPR measurements were performed on solutions of PMNs and plasma. When 300000 PMNs/mL were mixed with 5% plasma in phosphate-buffered saline in the presence of 50 mmol/L DMPO, no signal was observed. Repeated measurements with up to 1 million PMNs/mL and up to 50% plasma also showed no significant signal, confirming that the rat plasma did not cause activation of an oxidative burst from the human PMNs. To further confirm that the PMNs did not induce any activation of complement, red cell lysis assays were performed as described above. These assays demonstrated that mixture of human PMNs and rat plasma did not result in any measurable complement activation. If complement was intentionally activated with 1 mg/mL zymosan, however, marked red cell lysis and marked free radical generation were observed. Thus, these validation experiments demonstrated that there was no baseline complement activation, neutrophil activation, or alterations in preischemic function in this rat heart model perfused with human PMNs and rat plasma.
To determine if there were any adverse effects of human plasma on rat hearts, pilot studies were performed infusing human plasma into control rat hearts. Even at a 1:20 dilution, human plasma resulted in irreversible asystole. This appeared to be due to crossreactive human antibodies reacting with the rat antigens. We observed that this toxicity could be prevented by immunoabsorption of the human plasma with rat heart homogenate using the procedure described above. To verify that immunoabsorption of human plasma did not deplete the complement proteins, we performed experiments to determine if these complement proteins remained. EPR experiments were conducted with PMNs and immunoabsorbed plasma with 1 mg/mL zymosan added to activate the complement system of proteins. In the presence of zymosan, free radical generation was observed identical to that of native human plasma. In the presence of sCR1 (10 ,ug/mL), suppression of the complement pathway was observed, and free radical generation was abolished. These experiments demonstrated that the process of immunoabsorption of human plasma with rat heart homogenate at 4°C did not inactivate the complement system of proteins. Further validation of this was done with the measurement of complement activation by red cell lysis in the presence of PMNs and plasma. In the presence of zymosan (1 mg/mL), marked hemolysis was observed.
To verify that remixing of human PMNs and human plasma did not activate complement or cause other adverse reactions, all hearts studied were first subjected to control preischemic infusion of both the PMNs and human plasma, and it was observed in all hearts studied that after infusion left (Fig 2, top) (Fig 2, bottom) . This (Fig 3, top) . Thus, hearts treated with sCR1 exhibited a 2. (Fig 3, bottom) 16+1 mL/min for those hearts that did not receive sCR1 and 17±1 mL/min for the hearts treated with sCR1. Throughout the entire 45 minutes of reperfusion, however, marked differences were seen with higher recovery in the sCR1-treated hearts (Fig 8) . The final recovery of coronary flow was 12.8±1.6 mL/min in hearts treated with sCR1 versus 7.5±2.2 mL/min in untreated hearts (Fig 5, top) (Fig 5, bottom) 
Histology
Histologic sections were examined from hearts that were treated with and without sCR1. In hearts that received sCR1, the myofibrillar structure of the myocytes as well as the interstitial spaces appeared normal, whereas in hearts that were not treated with sCR1, areas of myocyte necrosis were seen as reported previously in this model.14 In both sCR1-treated and untreated hearts, PMNs were seen adherent to the endothelial surfaces of arterioles and capillaries; however, only in untreated hearts were PMNs noted to have migrated across the endothelium. As noted previously, in the absence of treatment, degranulating PMNs were observed adjacent to cardiac myocytes. Therefore, sections from sCR1-treated hearts appeared different from those of untreated hearts with PMNs only observed adherent to the endothelium without endothelial transmigration and myocardial structure appeared normal (Fig 6) .
Immunohistochemistry
Hearts were subjected to the protocol described above in the presence or absence of sCR1. These hearts were stained with monoclonal antibody to the C5b-9 attack complex using a standard immunoperoxidase method. Normal rat heart tissue failed to reveal any staining. Control, nonischemic rat hearts subjected to perfusion with neutrophils and plasma failed to demonstrate any staining. Standard controls using either no primary or no (Fig 7) . Therefore, in sCR1-treated hearts, there was marked diminution in complement deposition compared with untreated hearts.
Measurement of Free Radical Generation
It has been suggested that oxygen free radicals are important mediators of the myocardial injury that occurs on postischemic reperfusion23-25 and that PMNs are important sources of this radical generation. To assess if the complement blocker sCR1 could prevent this neutrophil-mediated free radical generation, experiments were performed to determine if sCR1 could prevent complement-mediated activation of the neutrophil oxi- dative burst and prevent the generation of reactive oxygen free radicals in vitro. Complement was activated with 1 mg/mL zymosan, a potent activator of the complement pathway, and added to PMNs in the presence or absence of sCR1. The overall kinetics of free radical generation was measured for a 35-minute period by EPR spectroscopy in the presence of the spin-trap DMPO, at a 50 mmol/L concentration. In the presence of zymosan, marked free radical generation was observed with prominent DMPO-OOH and DMPO-OH adducts signals. These signals were totally quenched in the presence of 200 U/mL SOD, demonstrating that the observed signals were derived from superoxide. The intensity of these radical signals peaked after 20 minutes. In the presence of sCR1, however, complete inhibition of free radical generation was observed (Fig  8) . Further experiments were performed in the isolated rat heart model to determine if sCR1 also prevented the generation of PMN-derived free radicals in the heart. Hearts were subjected to 20 minutes of global ischemia and reperfused with the presence or absence of sCR1. These hearts were also perfused with 40 mmol/L concentration of the spin-trap DMPO, and the coronary effluent was sampled every 20 seconds for the first 2, 5, 7.5, and, finally, 10 minutes of reflow. We have previously demonstrated in the presence of both PMNs and plasma that the total magnitude of free radical generation is increased with a prolongation in the duration of free radical generation. In isolated hearts treated with sCR1, the magnitude and duration of radical generation were observed to be less than that of hearts reperfused with PMNs and plasma in the absence of the drug. Radical generation in sCR1-treated hearts was similar to that observed in the absence of PMNs and plasma, consisting of a short burst peaking at 30 seconds of reflow with no radical generation observable after 2 minutes of reflow. In the absence of sCR1 treatment, radical generation was prolonged and persisted for more than 10 minutes as reported previously.14 Thus, reperfusion with sCR1 prevented the increased magnitude and duration of free radical generation that occurs in hearts secondary to PMN-mediated free radical generation. This suggests that complement is required for PMN-mediated free radical generation in the postischemic heart (Fig 8) . sCR1 has a molecular weight of 200 kd consistent with a deletion of 67 residues of the full-length receptor. 35 The mechanism of sCR1 inhibition of the complement pathway has been extensively investigated. Fearon et a118 suggested that sCR1 has the greatest potential of the RCA family because it has the specificity for binding C3b and C4b, with distinct sites for both proteins, thereby possessing the capacity for displacement of the catalytic subunits from the C3 or C5 convertases of both the pathways and also activating as cofactor for the degradation of C3b and C4b by factor 1.
In the present study, experiments were performed in an isolated rat heart model in the presence of either rat or human complement factors and human PMNs. sCR1 blocks formation of the membrane attack complex C5b-9 in both human plasma and rat plasma by interaction with the C3 and C5 convertase of both complement pathways. 16 '45 We have demonstrated that sCR1 has marked cardioprotective effects in preventing the neutrophil-mediated reperfusion injury that occurs secondary to the activation of complement. Efficacy was observed against either rat complement or human com-plement. Greater than twofold increased coronary flow was observed in the sCR1-treated hearts than in similar untreated hearts. In the hearts treated with sCR1, much lower end-diastolic pressures were observed demonstrating improved diastolic relaxation of the left ventricle, most likely secondary to decreased myocyte calcium loading. sCR1 treatment resulted in a more than twofold reduction in left ventricular end-diastolic pressure. Both postischemic recovery of left ventricular developed pressure and the rate-pressure product were markedly increased in the sCR1-treated hearts compared with untreated controls with a more than twofold increase seen. Thus, sCR1 treatment greatly improved the recovery of both contractile function and coronary flow in postischemic hearts. The recovery in left ventricular developed pressure, rate-pressure product, enddiastolic pressure, and coronary flow observed in the presence of sCR1 was identical to that of hearts subjected to ischemia in the absence of PMNs, plasma, or PMNs and plasma, demonstrating that sCR1 totally prevented complement-mediated and PMN-mediated injury (Table 1) .
Immunohistochemical staining of the tissue of hearts subjected to ischemia and reperfusion in the presence of PMNs and plasma demonstrated the presence of complement deposition throughout both ventricles with the C5b-9 attack complex localized primarily on the endothelium of the arterioles and capillaries. In normally perfused hearts in the presence of PMNs and plasma or in postischemic hearts in the absence of PMNs and plasma, complement deposition was not seen. In hearts subjected to ischemia and reperfusion in the presence of PMNs and plasma, sCR1 prevented this complement deposition. These studies demonstrate that complement is activated in ischemic myocardium with the deposition of the membrane attack complex on the coronary endothelium and that sCR1 effectively prevents this complement deposition.
In postischemic hearts, increased PMN adhesion was noted; however, sCR1 did not prevent this increase. No significant alternations in PMN accumulation or adherence were observed in the presence or absence of sCR1 in measurements of the arterial venous gradient in PMN concentration or the histologic visualization of PMNs adherent to the vascular endothelium. This suggests in this model that PMN adhesion is not complement dependent. The process of PMN adhesion is probably primarily controlled by the expression of PMN and endothelial adhesion molecules. In postischemic myocardium upregulation of adhesion molecule surface expression has been hypothesized to occur, and this process alone may be responsible for the increased PMN adhesion that was observed in the postischemic myocardium. In both in vivo canine and feline models of myocardial ischemia and reperfusion it has been demonstrated that specific antibodies to the CD18 neutrophil adhesion molecule can prevent neutrophil accumulation and decrease infarct size. 46 Electron paramagnetic resonance studies were performed that demonstrated that sCR1 could prevent the neutrophil-derived oxidative burst triggered by complement activation. sCR1 totally prevented the generation of superoxide and superoxide-derived free radicals that occurs in neutrophils incubated in the presence of activated complement. In the postischemic hearts, sCR1 prevented the amplification in the magnitude and duration of free radical generation that is observed in the presence of PMNs and plasma. Thus, sCR1 did not prevent PMN adhesion within postischemic myocardium, but it did prevent the complement-dependent process of free radical generation from these adherent PMNs. These data suggest that while the process of PMN adhesion within ischemic myocardium is complement independent, complement is required for PMN activation with the generation of reactive superoxide and superoxide-derived free radicals, which in turn cause tissue injury.
In summary, these studies demonstrate that complement-mediated neutrophil activation occurs in the postischemic heart. This process causes marked reperfusion injury with impaired contractile function and decreased coronary flow. Neutrophil adhesion was increased in postischemic myocardium, and this process was observed to be independent of the presence of complement proteins. Activation of the neutrophil oxidative burst, however, was observed to be complement dependent. sCR1 was observed to be a particularly potent inhibitor of this neutrophil-derived complement dependent postischemic injury. It totally prevented the neutrophil-derived alterations in contractile function and coronary flow and prevented neutrophil-derived free radical generation. Thus, sCR1 appears to be a promising therapeutic agent in the prevention of myocardial reperfusion injury. Since it is a recombinant human molecule, which is highly effective in inhibiting human complement, it should be suitable for extension to clinical use in humans.
